Novartis now expects its core operating profit to grow in the mid to high teens, after second-quarter results outpaced analysts’ expectations, boosted by revenue from its blockbuster treatments.
Anglo American cut its 2024 coal-production target after a fire incident at a major mine is set to suspend production for the rest of the year, while backing guidance for its key metals copper and iron ore.